Ramantamig
Based on 1 Customer Validation
Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 95%
- No. CAS: 2988886-91-3
- Peso molecular:153.279 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
Isotype
immunoglobulin (H-gamma1-scFvkh_L-lambda2)_scFvkh-G1(h-CH2-CH3)
Species Reactivity
Human
IC50 & Target
CD3E & GPRC5D & TNFRSF17
In Vitro
Ramantamig (72 h) potently induces T-cell-mediated cytotoxicity and activation in BCMA-GPRC5D dual-positive human multiple myeloma cell lines (MM.1S, H929, JIM-3, OPM-2) with sub-nanomolar to low nanomolar EC50 values, but has no effect on dual-negative myeloid cell lines[1].
Ramantamig (72 h) induces potent T-cell-mediated cytotoxicity and activation in H929-WT, H929-BCMA-KO, and H929-GPRC5D-KO human multiple myeloma cell lines, with significantly higher potency against dual-target-expressing H929-WT cells[1].
Ramantamig (48 h) potently induces T-cell-mediated cytotoxicity, T-cell activation, and proinflammatory cytokine production in H929 human multiple myeloma cells spiked into healthy human whole blood, with low nanomolar EC50 values[1].
Ramantamig (48 h) does not induce nonspecific T-cell activation or immune cell cytotoxicity in healthy human purified T cells or whole blood, except at very high concentrations (>10 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BCMA-GPRC5D dual-positive human multiple myeloma cell lines: MM.1S, H929, JIM-3, OPM-2; BCMA-GPRC5D dual-negative cell lines: MV-4-11, OCI-AML-3; pan-T cells from 6 healthy human donors
-
Concentration:dose-dependent (EC50 values reported)
-
Incubation Time:72 h
-
Result:Induced potent cytotoxicity in dual-positive MM cell lines with EC50 values of 0.002 nM (MM.1S), 0.005 nM (H929), 0.312 nM (JIM-3), and 0.019 nM (OPM-2).
Reached maximum cytotoxicity of 92.58% (MM.1S), 94.47% (H929), 61.22% (JIM-3), and 81.32% (OPM-2).
Induced T-cell activation with EC50 values of 0.010 nM (MM.1S), 0.008 nM (H929), 1.070 nM (JIM-3), and 0.062 nM (OPM-2).
Reached maximum T-cell activation of 75.03% (MM.1S), 85.90% (H929), 30.85% (JIM-3), and 45.95% (OPM-2).
Did not induce cytotoxicity or T-cell activation in dual-negative MV-4-11 or OCI-AML-3 cell lines.
In Vivo
Ramantamig (0.025-1 mg/kg; i.p.; twice weekly; 7 doses) induces dose-dependent tumor growth inhibition and complete regression in MM.1S multiple myeloma xenografts, with the 1 mg/kg dose achieving 109% ΔTGI and 100% tumor regression by day 34, and sustaining 100% complete regression by day 51[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (female, aged ~5 to 8 weeks, weighing ~20 g, T-cell-humanized, subcutaneous xenograft of RPMI 8226 cells)[1]
-
Dosage:0.1 mg/kg; 0.4 mg/kg; 1 mg/kg; 2.5 mg/kg
-
Administration:i.p.; twice weekly; 8 doses
-
Result:Induced tumor growth inhibition (ΔTGI) values of 38.4% at 0.1 mg/kg, 90.5% at 0.4 mg/kg, 106.2% (with 51.7% tumor regression) at 1 mg/kg, and 111.2% (with 95.2% tumor regression) at 2.5 mg/kg on day 38.
Achieved complete tumor regression in 2 of 9 mice in the 0.4 mg/kg group, 8 of 10 mice in the 1 mg/kg group, and 9 of 9 mice in the 2.5 mg/kg group by day 60.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (female, aged ~5 to 8 weeks, weighing ~20 g, T-cell-humanized, subcutaneous xenograft of MM.1S cells)[1]
-
Dosage:0.025 mg/kg; 0.1 mg/kg; 0.5 mg/kg; 1 mg/kg
-
Administration:i.p.; twice weekly; 7 doses
-
Result:Induced ΔTGI values of 72.9% at 0.025 mg/kg, 99.4% at 0.1 mg/kg, 108.6% (with 95.9% tumor regression) at 0.5 mg/kg, and 109% (with 100% tumor regression) at 1 mg/kg on day 34.
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
half-G1-lambda-scFvkh_scFvkh-h-CH2-CH3
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 Jurkat cells labeling CD3E with Ramantamig (HY-P991155, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
No. CAS 2988886-91-3
-
Appearance Liquid
-
Peso molecular 153.279 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
JNJ-79635322; JNJ-5322
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics Synaptic Plasticity & Brain Health
Synaptic plasticity is the activity-, experience-, development-, and injury-dependent modification of synaptic strength, number, and structure, and it remains a central mechanism for learning, memory, sensory adaptation, and brain health.
2026-06-18
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ramantamig Related Classifications
HY-P991155 Related Classifications
Powered by Bioz
Keywords
- Ramantamig
- 2988886-91-3
- JNJ-79635322
- JNJ-5322
- JNJ79635322
- JNJ 79635322
- JNJ5322
- JNJ 5322
- JNJ-5322
- CD3
- TNF Receptor
- Cluster of differentiation 3
- Tumor Necrosis Factor Receptor
- TNFR
- T cells
- patient-derived malignant plasma cells
- Fc receptors
- CD3ε
- CD138+ plasma cells
- BCMA
- human multiple myeloma cell lines
- multiple myeloma cells
- murine xenograft models
- GPRC5D
- Inhibitor
- inhibitor
- inhibit